White Paper: The Physician Practice Recapitalization Playbook
A physician practice recapitalization sells part or all of the practice's equity to outside capital while the physicians keep practicing and keep a stake. For most groups the decision comes down to one trade. A majority recap pays far more cash today, but the physicians accept a permanent pay cut and give up control. A minority deal keeps pay and control, but the owners take little or no cash. In our worked example of an 8-physician group with $3.0 million of EBITDA, the majority recap pays the owners $34.2 million at close. The minority deal pays them nothing at close and leaves $1.5 million a year of pay in place. The sections below give the multiples, the reset math, the rollover terms and the 16-week sequence that decide which side of that trade wins.
Data as of November 20, 2026. Every market figure names its source, population and period. Worked examples are hypothetical, and the arithmetic in them is ours.
Executive summary: five points that set 2026 recap terms
- Size sets the multiple. Sikich's Q3 2026 healthcare M&A update gives indicative physician practice ranges from 5 to 7x EBITDA below $1 million up to 11 to 13x above $5 million. Hypothetical: at $3 million of EBITDA, moving from 8x to 10x adds $6 million of enterprise value.
- Buyers are selective. Physician groups fell from 28% of global provider deals in 2021 to 23% in 2025, per Bain & Company's Global Healthcare Private Equity Report 2026. Of the 1,029 PE-backed US healthcare deals PESP tracked in calendar 2025, 664 were add-ons, about 65% by our arithmetic.
- The compensation reset is the biggest lever. Hypothetical: each $100,000 of physician pay permanently converted into EBITDA sells for $1.0 million at 10x. It also costs that $100,000 every year after close, and part of the value arrives as rolled equity, not cash.
- Cash at close differs more than headline value. In our worked example, a majority recap pays the eight owners $34.2 million at close. A minority growth deal on the same practice pays them nothing at close, because the investor's $6 million goes into the practice.
- Regulatory work can set the calendar. State transaction notice laws, federal antitrust review for larger deals and corporate practice rules can each move the closing date or change the structure. Map them before the LOI, not after it.
1. Six recap structures and what each one costs the physician owner
| Structure | What owners sell | Cash to owners at close | Who controls after close | Typical counterparty | Main cost to physicians |
|---|---|---|---|---|---|
| Majority recap with rollover | Control of the practice or MSO, with a minority stake rolled into holdco | Highest | Investor | PE platform or add-on buyer | Comp reset, loss of control, holdco debt sits ahead of rolled equity |
| Minority growth recap | Less than 50%, usually as new shares | Little or none if the investment is primary capital | Physicians, with investor vetoes | Growth equity, family office | Lower price per point, protective provisions, preferred return |
| Dividend recap | No equity | Moderate, funded by debt | Physicians | Bank, private credit | Debt service, covenants, personal guarantees in small deals |
| MSO affiliation | Nonclinical assets and management rights. The professional entity stays physician-owned | Moderate to high | MSO runs the business side | PE-backed MSO | Management fee, state corporate practice limits |
| Hospital acquisition | The whole practice. Physicians become employees | Low for small groups | Hospital | Health system | Small primary care practices can price near asset value |
| Minority equity plus revenue participation | A minority stake plus a share of revenue, where the law allows | Little or none if primary capital | Physicians | Family office | Legal availability is narrow, and the payment comes off the top line |
Choose the structure by objective:
| If your priority is | Lead with | Why it fits | What to watch |
|---|---|---|---|
| Maximum cash now | Majority recap with rollover | Priced on pro forma EBITDA after the reset | The pay cut is permanent |
| Keeping control and current pay | Minority growth recap | Priced on reported EBITDA, no reset | No owner liquidity unless the investor also buys existing shares |
| Liquidity without selling equity | Dividend recap | Debt funds the payout | Covenants and guarantees |
| Growth capital with no fund clock | Family office minority stake | No forced sale in year five | Preferred return and redemption terms |
| Ending management burden | MSO affiliation or hospital employment | Someone else runs the business side | Management fee, or a low price for small groups |
See the healthcare capital stack chart.
How a majority recap pays, and at which multiple. A majority recap pays twice: once in cash at close and again through rolled equity at exit. The two payments are priced at different multiples. A group sold as an add-on receives an add-on multiple at close. If the physicians roll into the platform holdco rather than their own operating company, that equity rides the platform's multiple at exit. Only a group large enough to anchor a new platform gets platform pricing at close. Groups approaching the $5 million EBITDA band should test the market as a platform candidate before accepting add-on terms. Below $1 million of EBITDA, the majority recap competes with hospital employment and with small-business sale prices. The healthcare recapitalization guide covers minority, majority and dividend mechanics in more detail.
Hospitals are a weak bid for small groups. Kaufman Hall's Q3 2026 M&A Quarterly Activity Report press release (October 13, 2026) reports a year-to-date hospital operating margin of 2.5% including allocations, with nearly 43% of hospitals operating at a loss, both as of August 2026. Non-labor expense per adjusted discharge rose 6% year to date over 2025, with drug expense up 6% and supply expense up 5%. Hospital M&A is concentrated at the top. The 16 hospital and health system deals announced in Q3 2026 carried $8.2 billion of transacted revenue, and the average seller had nearly $586 million in annual revenue.
At the practice level, Buckhead FMV's database of 187 US healthcare services control transactions announced January 2023 to October 2026 shows hospital purchases of individual primary care practices, largely in West Virginia, clustering at 0.05x to 0.15x revenue. Buckhead reads that range as payment for equipment and records rather than goodwill. These deals drive the same dataset's primary care segment median of 0.11x revenue. Both figures describe a small set of hospital-bought primary care practices and do not carry over to specialty groups or other markets.
2. Who is buying physician groups in 2026: deal counts by buyer and specialty
| Metric | Figure | Population | Source and date |
|---|---|---|---|
| Physician groups' share of provider deals | 28% (2021) to 23% (2025) | Global provider transactions | Bain, Global Healthcare PE Report 2026 |
| PE-backed healthcare deals | 1,029 (151 buyouts, 664 add-ons, 214 growth) | US healthcare, all subsectors, calendar 2025 | PESP, 2025 in Review |
| Outpatient care provider deals | 148, including 119 add-ons | US outpatient providers, PE-backed, 2025 | PESP data reported by Becker's ASC Review |
| Top outpatient subsectors by deal count | Dermatology 24, eye care 22, oncology 9 | Same as above | PESP data reported by Becker's ASC Review |
| Physicians employed by hospitals or corporate entities | 82.0% (59.7% hospitals, 22.3% corporate entities) | US physicians, as of January 1, 2026 | PAI-Avalere data reported by Axia Growth |
| Physicians in a PE-owned practice | 6.5% in 2024, up from about 4.5% in 2020 and 2022 | US physicians, AMA Physician Practice Benchmark Survey | AMA data reported by Axia Growth |
| Hospital and health system deals announced | 16 in Q3 2026, $8.2 billion transacted revenue | US hospitals and health systems | Kaufman Hall press release, October 13, 2026 |
| Hospital transactions announced, annual | 46 in 2025 (lowest since tracking began in 2011), 56 through Q3 2026 | US hospitals and health systems | Kaufman Hall data reported by Becker's Hospital Review |
| Physician and clinical services spending | $1,109.7 billion in 2024. Projected 5.5% average annual growth, 2025 to 2034 | US national health expenditure | CMS NHE fact sheet |
Five conclusions follow.
Add-ons dominate. Add-ons were 119 of 148 PE-backed outpatient provider deals in 2025, or 80% by our arithmetic on PESP data reported by Becker's ASC Review. Most independent groups will be priced as add-ons into an existing platform. Dermatology and eye care, with 46 of the 148 deals between them, had the most buyer activity. A group in those specialties should expect more than one platform to look.
Independent groups are now the minority. With 82.0% of US physicians employed by hospitals or corporate entities as of January 1, 2026, per PAI-Avalere data reported by Axia Growth, an independent group with clean data and a stable roster is a scarce asset. Buyers compete for those groups. They discount the rest.
The spending base still grows. The CMS National Health Expenditure fact sheet puts physician and clinical services spending at $1,109.7 billion in 2024 and projects 5.5% average annual growth from 2025 to 2034. Medicare spending reached $1,118.0 billion in 2024, 21% of total health spending. Medicare's share of a practice's collections drives its exposure to annual fee schedule changes, and buyers price that directly.
The value-creation thesis has changed. Bain reports that the playbook now extends beyond buy-and-build to operational efficiency, including AI and analytics. Buyers will underwrite your revenue cycle, scheduling and coding data alongside your physician count. Bain also cites Cardinal Health's acquisition of GI Alliance from its physician owners and Apollo Global Management, a strategic exit for a PE-backed physician platform.
Hospital-based groups carry contract risk. Georgetown CHIR reports that PeaceHealth replaced its long-standing emergency group, Eugene Emergency Physicians, with Lane Emergency Physicians, a practice solely owned by an Illinois physician affiliated with the MSO ApolloMD. Buyers of anesthesia, emergency and hospitalist groups price the hospital contract term and renewal history before they price EBITDA.
The US is the market. Bain notes that scale physician group investment is far less common in Europe, where national markets and regulation are fragmented. In Asia-Pacific, physician groups are an uncommon theme and provider deals center on health systems.
3. Valuation: EBITDA size bands set the multiple before specialty does
The bands below are Sikich's indicative ranges for physician practices in its Q3 2026 update. Treat them as directional. Specialty, payer mix and ancillary revenue move a specific group within a band.
| Practice EBITDA | Indicative EV/EBITDA (Sikich, Q3 2026) | Value at band midpoint (hypothetical, our arithmetic) |
|---|---|---|
| Below $1 million | 5 to 7x | $0.8M EBITDA at 6x = $4.8M |
| $1 to 3 million | 7 to 9x | $2.0M EBITDA at 8x = $16.0M |
| $3 to 5 million | 9 to 11x | $4.0M EBITDA at 10x = $40.0M |
| Above $5 million | 11 to 13x | $6.0M EBITDA at 12x = $72.0M |
How the platform premium fits the bands. Sikich also reports that, by specialty, platforms command a four- to eight-turn premium over add-on practices. The two findings describe overlapping effects. Platforms are usually the larger groups, so most of that premium is the distance between the bottom and top size bands. Read the premium as the payoff for growing into platform scale, not as turns added on top of your band. A $3 million group bought as a tuck-in prices off the $1 to 3 million or $3 to 5 million band. It does not earn 15x because a platform in its specialty did.
Specialty and adjacent segments. Sikich's Q3 2026 update gives sub-sector ranges that show the platform-versus-add-on spread inside a single specialty.
| Segment (Sikich, Q3 2026) | Indicative EV/EBITDA | Trend vs 2025 |
|---|---|---|
| Ambulatory surgery centers | Single-specialty 5 to 8x, multispecialty 6 to 10x, regional operators 11 to 17x. Median ASC multiple 7.9x in 2025, the highest in at least eight years | Up |
| Dental (DSOs) | Platforms 9 to 11x, add-ons 5 to 8x, practices 5 to 9x | Flat |
| Urgent care | 3 to 7x under $10M revenue, 6 to 11x at $10 to 50M revenue | Not compared |
| Home health and hospice | Small agencies typically mid-single digits. Enhabit take-private at 10.2x | Down |
Dental shows the pattern most clearly. The same specialty prices at 5 to 8x as an add-on and 9 to 11x as a platform. Buckhead FMV's ASC segment median of 12.4x EBITDA sits above Sikich's 7.9x 2025 median because Buckhead's figure covers control transactions with disclosed EBITDA from January 2023 to October 2026, a population that leans toward larger deals. The two figures measure different populations and are not a like-for-like comparison.
For market context, Sikich reports PitchBook's median for PE-backed healthcare services buyouts at 13.6x EBITDA in 2025, on an implied median target EBITDA of roughly $33 million. That population is far larger than a typical practice, so it sits above every band in the practice table.
See the healthcare multiples by segment and size chart.
A second size view, from closed small-business sales. Axia Growth's healthcare-sector closed-sale data (as of October 28, 2026) shows the same step-up in a different population. The table covers closed sales in the healthcare sector as a whole, not physician practices alone, drawn from Axia's dataset of 4,554 de-identified closed small-business sales. The first three bands are priced on seller's discretionary earnings (SDE), which includes owner pay, so they are not comparable to EBITDA multiples. Axia reports no $3 million to $5 million band.
| Size band (healthcare sector, Axia Growth) | Deals | Median multiple | Middle half (25th to 75th percentile) |
|---|---|---|---|
| Under $500K SDE | 182 | 3.4x SDE | 2.7x to 4.2x |
| $500K to $1M SDE | 42 | 3.4x SDE | 2.5x to 4.4x |
| $1M to $2M SDE | 22 | 3.3x SDE | 2.7x to 7.5x |
| $2M to $3M EBITDA | 13 | 5.1x EBITDA | 3.1x to 10.9x |
| $5M to $10M EBITDA | 14 | 8.8x EBITDA | 3.4x to 10.7x |
| $10M+ EBITDA | 17 | 12.9x EBITDA | 9.4x to 18.5x |
The spread inside each band is wide and the samples are small. A median is a starting point, not a price.
A third view, across all healthcare services. Buckhead FMV's 187 control transactions (announced January 2023 to October 2026) produced an overall median of 9.6x EBITDA across the 68 deals with positive EBITDA, and 10.1x excluding distressed sales. Buckhead sorts this view by deal value, not by EBITDA. Deals above $200 million traded at a median 11.2x EBITDA. Deals below $10 million traded at a median 2.8x EBITDA and 0.27x revenue. That small-deal bucket includes the hospital purchases of primary care practices priced near asset value, and Buckhead notes that many state-filing prices reflect partial interests or negotiated terms rather than market tests. It sits well below Sikich's 5 to 7x band because it measures a different population. A healthy specialty group with $1 million of EBITDA should not price off it.
Revenue multiples mislead in physician deals. Damodaran's January 2026 data on US public companies shows healthcare support services (104 firms) at 0.46x EV/sales and a 2.99% pre-tax operating margin, against 1.69x and 12.86% for hospitals and healthcare facilities (31 firms). Margin drives the gap. Buyers price practices on adjusted EBITDA. Run your own band check with the practice valuation calculator and compare segment benchmarks in the valuation multiples guide.
What moves a practice up within its band:
- [ ] Ancillary revenue (imaging, lab, infusion, ASC) with a completed compliance review for each line
- [ ] Payer mix and contract rates at or above market, with contracts that are assignable
- [ ] A physician roster with signed post-close employment terms and no planned departures inside the hold period
- [ ] Three years of accrual financials and a sell-side quality of earnings report
- [ ] Multiple sites and a credible add-on pipeline, which makes the group a platform candidate
4. The compensation reset: how pro forma EBITDA is built and what it costs
In a physician recap, the buyer pays for profit after physician pay is reset to a post-close level. Reported EBITDA already deducts what the physicians are paid today. The reset deducts a lower post-close amount instead. The difference becomes EBITDA, and the buyer pays a multiple on it.
Worked example (hypothetical, our arithmetic), 8-physician group. Physician pay means all salary, bonus and benefits paid to the eight owner-physicians for clinical and administrative work. Distributions of profit above that are not an expense and are not deducted. The post-close pay level of $312,500 is an assumption chosen for illustration, a 37.5% cut. The right level depends on specialty and market.
| Line | Before close (reported) | After close (pro forma) |
|---|---|---|
| Net collections | $20.0 million | $20.0 million |
| Operating costs other than physician pay (staff, rent at market, supplies, overhead) | $13.0 million | $13.0 million |
| Physician pay, 8 physicians | $4.0 million ($500,000 each) | $2.5 million ($312,500 each, assumed) |
| EBITDA | $3.0 million | $4.5 million |
| Change in EBITDA | +$1.5 million ($187,500 per physician) |
| Valuation step | Amount |
|---|---|
| Pro forma EBITDA | $4.5 million |
| Multiple (within Sikich's $3 to 5 million band) | 10x |
| Enterprise value | $45.0 million |
| Value created by the reset ($1.5 million × 10) | $15.0 million |
| Value of reported EBITDA alone ($3.0 million × 10) | $30.0 million |
| Annual pay forgone by the physicians, every year after close | $1.5 million |
The reset is a sale of future income. The $15.0 million equals ten years of forgone pay, but not all of it arrives as cash.
How much of the reset value is cash (hypothetical, our arithmetic, base case from Section 6). At 4.0x entry debt, the physicians take $34.2 million in cash and roll $10.8 million of equity. The cash is funded by $18.0 million of new debt plus the sponsor's $16.2 million share of the $27.0 million equity, so it already reflects the entry debt. Cash is 76% of the $45.0 million enterprise value. Allocating the reset in the same proportion, $11.4 million of the $15.0 million arrives as cash at close and $3.6 million sits in rolled equity until exit.
Reset breakeven on the cash portion (our arithmetic, this scenario only). Assumptions, stated in the table: illustrative tax rates rather than any owner's actual rates, no state or payroll tax, no fees or escrow, no investment return on proceeds and no discounting. The result describes this example, not a general threshold.
| Line | Pre-tax | After tax |
|---|---|---|
| Reset value paid in cash at close (76% of $15.0 million) | $11.4 million | $8.66 million (assumes an illustrative 24% tax rate on all of it) |
| Reset value held in rolled equity | $3.6 million | Recovered only at exit (assumes tax-deferred rollover) |
| Pay forgone each year | $1.5 million | $0.945 million (assumes an illustrative 37% tax rate on pay) |
| Years until forgone pay equals the cash portion | 7.6 | 9.2 |
On these assumptions, the cash alone covers about nine years of after-tax forgone pay. A lower tax rate on the sale lengthens the breakeven and a higher one shortens it. The actual tax treatment of sale and rollover proceeds depends on the transaction structure, so confirm it with your own tax advisor. Physicians who expect to practice longer than that are relying on the rolled equity to make up the difference. Any portion of the price taxed as ordinary income shortens the breakeven. Investing the proceeds lengthens it. Without growth in the rolled equity, the reset is an advance against your own salary. The deal proceeds calculator converts headline value to cash at close.
Post-close pay has to stand on its own. Benchmark the reset against independent specialty survey data before you agree to it, such as the Medscape Physician Compensation Report, which is published each spring. The 2025 edition was released April 15, 2025. Use the most recent edition available when you benchmark. Check the staff wage assumptions behind the $13.0 million cost line against current BLS data for the health care and social assistance sector. A comp plan that pays below market loses physicians, and departing production comes straight out of EBITDA. Referral questions about the comp formula belong in the Section 5 review and are covered in the healthcare compliance due diligence guide.
Quality of earnings items that move pro forma EBITDA:
| Item | Buyer's treatment |
|---|---|
| Personal expenses run through the practice | Added back if documented |
| Rent paid to a physician-owned real estate entity | Reset to market. Below-market rent lowers EBITDA when reset. Above-market rent raises it |
| Routine copay waivers | Flagged. Buyers want a written waiver policy and a file showing the basis for each waiver |
| Ancillary income from arrangements without a completed compliance review | Excluded or escrowed |
| One-time payer settlements | Removed |
| Departing physician production | Set by the transition terms. Buyers remove it unless a signed replacement, a patient transition plan or an earnout supports retention |
Prepare before the buyer's accountants arrive. The QoE prep checklist lists the schedules.
5. Regulatory gates: what to settle before the LOI
Regulatory review can set the closing date and change the structure. Which reviews apply depends on deal size, buyer type and every state where the group has sites, patients or billing. Build the review map into the LOI's outside date, not the closing checklist. A deal whose outside date falls before a required review ends gets re-traded or dies.
High-risk area: questions to take to your own attorney before the LOI is drafted. Rules on referrals, practice ownership and transaction review can affect timing or structure, and they differ by state.
- Which transaction reviews or notices apply to this deal, given its size, the buyer type and every state where we have sites, patients or billing, and how long could each one take?
- Does any state where we practice limit investor or MSO control of a physician practice, and does that push us toward an MSO affiliation?
- Will our ancillary lines, leases and medical director agreements hold up in a buyer's compliance review?
- Is the proposed post-close comp formula consistent with fair market value, and does any part of it vary with referrals?
- Can a revenue-based payment to an investor be used in every state where we bill?
- Will our existing and proposed restrictive covenants hold in each state where our physicians practice?
The healthcare compliance due diligence guide covers the referral, ancillary and ownership questions, and the healthcare M&A process guide covers review timing. Georgetown CHIR describes Oregon as one state that has tightened limits on investor and MSO control.
What a longer review calendar costs the 8-physician group (hypothetical, our arithmetic on the Section 4 and Section 6 figures). Time itself is cheap. The risk is what can happen to the price while the review runs.
| While the review runs | Effect on the owners | Value in the 8-physician example |
|---|---|---|
| Each month the close slips | Owners keep pre-reset pay until close | $125,000 a month of pay above the post-close level ($1.5 million ÷ 12) |
| Each month the close slips | Cash at close arrives later | About $114,000 a month of forgone return on $34.2 million, assuming 4% a year |
| Net monthly effect of delay | Retained pay slightly exceeds the forgone return | About $11,000 a month in the owners' favor, before fees |
| One physician leaves before close, equal production assumed | Buyer removes that physician's share of pro forma EBITDA | $562,500 of EBITDA ($4.5 million ÷ 8), or $5.6 million of value at 10x |
| Buyer re-trades the multiple from 10x to 9x | Price falls on the same pro forma EBITDA | $4.5 million less enterprise value ($45.0 million to $40.5 million) |
| Exclusivity runs out with no competing bid still live | Owners lose their main source of leverage | Not priced, but every line above becomes easier for the buyer to ask for |
On these figures, delay by itself is close to neutral for the owners, but that result is fragile. It compares pre-tax pay with a pre-tax return, ignores that the rolled equity's exit clock may start later, and reverses if the assumed return is a little above 4%. A single physician departure during a long review costs $5.6 million of value, which no monthly carrying effect comes close to offsetting. The calendar matters less than how well the LOI holds the price while it runs.
Protections to put in the LOI before the review starts:
- [ ] Multiple fixed on a defined pro forma EBITDA, with the add-back schedule attached (Section 8, point 1)
- [ ] Signed retention intent from every physician before the LOI is signed, not after
- [ ] An outside date set from the mapped review calendar, with a buffer
- [ ] Exclusivity that falls away if the buyer re-trades the price
- [ ] Interim operating covenants that let the practice keep recruiting and running normally until close
- [ ] At least one alternative bidder kept warm until the review is complete
Documents the review needs in week 1. The calendar can only be mapped as fast as the practice produces the facts.
- [ ] Every site, every state where patients are seen and every state where the practice bills
- [ ] An entity chart covering the professional entity, any MSO, real estate entities and ancillary entities, with each physician's ownership in each
- [ ] Every lease, medical director agreement, ancillary arrangement and services contract with a referral source or a physician-owned entity
- [ ] Current physician employment agreements, the comp formula and the proposed post-close pay level from Section 4
- [ ] Existing restrictive covenants for every physician
- [ ] The structures under consideration from Section 1, including any revenue-based payment
- [ ] The bidder list by type: PE platform, MSO, hospital, family office
- [ ] The intended outside date and exclusivity term
How review findings reprice the LOI (hypothetical, our arithmetic on the Section 4 example):
| If the review finds | What changes in the deal | What it is worth in the 8-physician example |
|---|---|---|
| An additional transaction review on the calendar | Outside date, exclusivity and interim operating covenants extend to cover it | Price holds only if the LOI fixes the multiple on a defined pro forma EBITDA (Section 8, point 1) |
| An ancillary line that has not been cleared | Buyer excludes or escrows its income | Each $100,000 of EBITDA excluded removes $1.0 million of value at 10x |
| Limits on investor control of the practice | Deal moves toward an MSO affiliation, with a management fee in place of direct ownership | Structure and fee replace the control premium in Section 1 |
| Questions about the post-close comp formula | Reset terms are redrafted before the LOI | The $1.5 million reset carries $15.0 million of enterprise value at 10x |
| A revenue-based payment that cannot be used in every billing state | Fallback to a fixed fee or pure equity | A 4% royalty on $20 million costs $800,000 a year, so the equity price must move with it (Section 7) |
| A covenant unlikely to hold in a key state | Retention shifts to rollover vesting or an earnout | Departing production comes out of EBITDA at the buyer's multiple |
If the deal moves toward an MSO affiliation, the management services organizations guide covers how those structures are set up.
6. Rollover equity: 10 terms that decide whether the second bite pays
| # | Term | What to ask | What it changes |
|---|---|---|---|
| 1 | Entity | Do we roll into the operating company or the top holdco? | Holdco rollover shares in add-on value and the platform exit multiple |
| 2 | Price | Is the rollover valued at the same price as the cash portion? | A discount to the cash price hands value to the sponsor on day one |
| 3 | Security class | Is it the same class as the sponsor's? | Preferred ahead of common changes the exit split |
| 4 | Leverage | How much debt sits ahead of us, now and after add-ons? | Sikich reports PitchBook median entry leverage of 5.2x for PE-backed healthcare services buyouts in 2025. A single-group recap typically carries less |
| 5 | Dilution | What are the option pool and add-on issuance rules? | Unpriced dilution shrinks your percentage |
| 6 | Departure | What happens to rolled equity on death, disability or termination? | Repurchase at cost instead of fair value is a forfeiture |
| 7 | Tag and drag | Can we sell when the sponsor sells, and on the same terms? | This protects your exit price |
| 8 | Restrictive covenants | How long and how wide is the noncompete? | A covenant that will not hold in your state is a negotiating chip, not protection |
| 9 | Information | Do we get quarterly financials and a board observer seat? | You cannot value what you cannot see |
| 10 | Exit horizon | What is the sponsor's fund life and target hold period? | It sets when the second bite arrives |
Second-bite math (hypothetical, our arithmetic, continuing Section 4). Assumptions:
- The group anchors a new platform at 10x pro forma EBITDA of $4.5 million. The practice has no debt before close.
- Base case entry debt is 4.0x pro forma EBITDA, below the 5.2x PitchBook median Sikich reports for buyouts with roughly $33 million of EBITDA. The comparison case uses 5.2x.
- The physicians roll 40% of holdco equity. In the base case that is $10.8 million, 24% of the $45.0 million price. Debt funds part of the price, so a 24% rollover of value buys a 40% equity stake. The 40% is an assumption for illustration.
- Over five years the platform buys add-on groups with $4.5 million of combined EBITDA at 7x, the low end of Sikich's $1 to 3 million band. Purchase cost is $31.5 million, funded entirely with new debt. No new equity is issued, so the physicians' 40% is not diluted. This is the best case for the physicians' share.
- Free cash flow after interest repays $10.0 million of debt in the base case. The 5.2x case carries $5.4 million more entry debt. At an assumed constant 9% rate on that extra balance, interest rises about $0.49 million a year, or about $2.4 million over five years, so repayment falls to $7.6 million. Debt balances are simplified to these totals.
- No organic growth. Exit EBITDA of $9.0 million comes from the base group plus the add-ons.
- Exit at 12x, inside Sikich's above-$5 million band.
- All figures are pre-tax and ignore transaction fees, escrow and working capital adjustments.
| Step | Base case: 4.0x entry leverage | Comparison: 5.2x entry leverage |
|---|---|---|
| Enterprise value at close | $45.0 million | $45.0 million |
| Entry debt | $18.0 million | $23.4 million |
| Equity value at close | $27.0 million | $21.6 million |
| Physicians roll 40% of equity | $10.8 million | $8.64 million |
| Rollover as a share of the $45.0 million price | 24% | 19% |
| Cash to physicians at close (entry debt plus the sponsor's 60% equity check, which equals EV less rolled equity, before fees, escrow, working capital and tax) | $34.2 million ($18.0M debt + $16.2M sponsor equity) | $36.36 million ($23.4M debt + $12.96M sponsor equity) |
| Plus add-on debt | $31.5 million | $31.5 million |
| Less debt repaid from free cash flow | $10.0 million | $7.6 million |
| Debt at exit | $39.5 million (4.4x exit EBITDA) | $47.3 million (5.3x exit EBITDA) |
| Exit enterprise value ($9.0 million × 12) | $108.0 million | $108.0 million |
| Equity at exit | $68.5 million | $60.7 million |
| Physicians' 40% | $27.4 million | $24.28 million |
| Multiple on rolled equity | 2.5x | 2.8x |
| Total to physicians, cash plus roll at exit (pre-tax, undiscounted) | $61.6 million | $60.64 million |
Sensitivity to the exit multiple (same assumptions, our arithmetic):
| Exit multiple | Exit EV | Base: physicians' 40% | Base: multiple on roll | Base: total to physicians | 5.2x: physicians' 40% | 5.2x: multiple on roll | 5.2x: total to physicians |
|---|---|---|---|---|---|---|---|
| 12x | $108.0M | $27.4M | 2.5x | $61.6M | $24.28M | 2.8x | $60.64M |
| 10x | $90.0M | $20.2M | 1.9x | $54.4M | $17.08M | 2.0x | $53.44M |
| 8x | $72.0M | $13.0M | 1.2x | $47.2M | $9.88M | 1.1x | $46.24M |
Read the base case as the headline. Higher entry leverage pays $2.16 million more cash at close and lifts the multiple on a smaller roll at a 10x or 12x exit. It loses at 8x. The physicians' total is about $0.96 million lower in every row, which is their 40% share of the extra interest. A higher multiple on the roll is not a better outcome.
The second bite comes from two sources: buying add-ons at 7x and selling the combined EBITDA at 12x, and moving the platform into a higher size band. The reset was already paid for at close. A full-debt add-on program puts 4.4x to 5.3x leverage on the platform at exit. If the sponsor funds add-ons partly with new equity, leverage falls but the physicians' 40% is diluted and the multiple on the roll falls with it. Run your own case in the rollover equity calculator and work through the physician rollover equity checklist before signing.
7. Family office minority capital, and where revenue participation fits
Family offices buy minority stakes in physician groups without a fund clock forcing a sale in year five. The physicians keep control and skip the compensation reset. The trade is liquidity. The investor's money usually goes into the practice, not to the owners.
Hypothetical minority deal (our arithmetic), same 8-physician group as Section 4. A family office invests $6 million of new capital for 20% of the equity. That implies a $30 million post-money and $24 million pre-money equity value. The practice carries no debt, so pre-money equity equals enterprise value. The $6 million is primary capital and goes onto the practice balance sheet. The deal is pure equity with no revenue-based payment, so EBITDA stays at the reported $3.0 million.
What the eight physicians hold the day after close (our arithmetic):
| Item | Majority recap (Section 6 base case) | Minority equity stake |
|---|---|---|
| Cash to physicians at close, before fees, escrow and tax | $34.2 million | $0 |
| New capital into the practice | $0 | $6.0 million |
| Equity kept | 40% of holdco, $10.8 million | 80% of the practice, $24.0 million at post-money |
| Annual physician pay | $2.5 million | $4.0 million |
| Control | Investor | Physicians |
Liquidity is the larger difference. The minority deal funds growth or retires practice obligations. It does not put money in the owners' hands unless the investor also buys existing shares, which is a separate negotiation and a separate price. Before taking a family office's term sheet, search its fund vehicles on SEC EDGAR for Form D filings to see what it has raised and backed.
Why the minority deal prices below the $45 million majority recap. The comparison holds because neither structure carries practice-level debt before close, so equity value and enterprise value match. If the practice has debt, compare enterprise values, not equity checks. The minority deal is priced on reported EBITDA of $3.0 million because the physicians keep their $4.0 million of pay. $24 million is 8.0x reported EBITDA. At exactly $3.0 million, the group sits on the boundary between Sikich's $1 to 3 million and $3 to 5 million bands, so the 8x reflects two effects together: a lower size band than the $4.5 million pro forma figure and a minority stake without control. The $21 million gap breaks down as follows (our arithmetic):
| Driver | Value |
|---|---|
| Compensation reset not made ($1.5 million × 10x) | $15.0 million |
| Lower multiple on $3.0 million of reported EBITDA, 8x rather than 10x (size band and minority position combined, not separable here) | $6.0 million |
| Total gap | $21.0 million |
The physicians keep $1.5 million a year of pay and control in exchange.
Revenue participation: narrow, and priced as part of the stake. Some family offices ask for a percentage of revenue alongside the equity. In physician practices this structure is the exception, and a practice that bills in several states may not be able to use it everywhere. Whether it can be used at all is a question to take from the healthcare compliance due diligence guide to your own attorney. Where it is used, it comes off the top line before staff, rent or physicians are paid.
| Royalty on $20 million of revenue (hypothetical, our arithmetic) | Annual payment | Share of EBITDA at 15% margin ($3.0M) | Share of EBITDA at 25% margin ($5.0M) |
|---|---|---|---|
| 1% | $200,000 | 6.7% | 4.0% |
| 2% | $400,000 | 13.3% | 8.0% |
| 3% | $600,000 | 20.0% | 12.0% |
| 4% | $800,000 | 26.7% | 16.0% |
A royalty is a second price for the same stake. In the example above, a 4% royalty at flat revenue would take $800,000 a year and cut EBITDA available to the owners from $3.0 million to $2.2 million. At the same 8x, that is $17.6 million of pre-money value instead of $24 million. Uncapped, the royalty stream is worth about $6.4 million to the investor at that multiple. An investor asking for 20% at $24 million pre-money plus a 4% royalty is asking for that $6.4 million on top. Owners should either raise the equity price, lower the stake or cap the royalty. A cap shortens the stream and lowers its value. If the structure goes forward, define the base as net collections rather than gross charges, state the cap and step-down rate, and agree a fixed-fee or pure-equity fallback in the term sheet.
The family office healthcare investing guide and the family office capital white paper cover how these investors source and underwrite deals.
8. Term sheet negotiation: 12 points to settle before signing the LOI
Exclusivity moves the leverage to the buyer. Settle these points while competing bids are still live.
| # | Point | Owner's target |
|---|---|---|
| 1 | Valuation basis | Multiple stated on a defined pro forma EBITDA, with the add-back schedule and post-close pay level attached |
| 2 | Compensation reset | Pay per physician, the productivity formula and the term in writing |
| 3 | Cash and rollover split | Fixed percentages, with the rollover priced the same as the cash |
| 4 | Working capital peg | Trailing 12-month average, not a seasonal high |
| 5 | Escrow and indemnity | Size, survival period and R&W insurance |
| 6 | Earnout | Metrics the physicians control, with a cap and an end date |
| 7 | Exclusivity | A short, fixed term with a fall-away if the price is re-traded |
| 8 | Regulatory timing | Outside date that covers every mapped review, plus a buffer for extended review |
| 9 | Governance | Board seats and clinical decisions reserved to physicians |
| 10 | Restrictive covenants | Scope and duration your counsel expects to hold in your state |
| 11 | Real estate | Separate lease at fair market rent, or a separate sale |
| 12 | Minority investor rights | Preferred return, liquidation preference and any redemption or put right, each with a stated rate and schedule |
Compare offers on one table. Bidders quote headline value in different ways. Convert every offer to the same five lines before you rank them:
| Line | What to compute |
|---|---|
| Enterprise value | Multiple × the EBITDA definition in the offer, adjusted to a common pro forma basis |
| Cash at close | EV less rolled equity, less escrow, fees and working capital adjustment |
| Rolled equity | Dollar amount, percentage of holdco, security class and debt ahead of it |
| Annual physician pay after close | Per physician and in total |
| Recurring cost to the practice | Management fees, preferred returns or any revenue-based payment |
The LOI red flags checklist lists the terms that most often reprice a deal after exclusivity.
One-page action plan: 16 weeks from decision to signed LOI
The plan ends at a signed LOI. Closing follows the longest applicable regulatory review, which is mapped in weeks 1 to 3.
Steps overlap in practice; regulatory clocks often run in parallel with confirmatory diligence.
Text version
- 1. Readiness (before going to market): Sell-side QoE, billing and coding audit, contracts and licenses cleaned up, data room built
- 2. Positioning and buyer list: Teaser, confidential information memorandum, model; PE platforms, add-on buyers, strategics, family offices
- 3. First-round bids: NDA, management materials, indications of interest; narrow to a short list
- 4. Management meetings and LOI: Site visits, second-round bids, negotiate price mechanics, rollover, earnout; sign LOI with exclusivity
- 5. Confirmatory diligence: Buyer QoE, legal, regulatory, payer and provider diligence, RWI underwriting
- 6. Regulatory reviews (if any apply): Some deals need federal or state filings before closing. Whether any apply, and how long they take, depends on the deal, so the timing comes from your healthcare attorney
- 7. Definitive agreement and close: Purchase agreement, employment and rollover documents, funds flow, escrow; post-close integration and earnout period
HealthcareInvestmentBanking.com process map
| Week | Action | Output | Lead |
|---|---|---|---|
| 1 to 2 | Choose a structure: majority, minority, dividend, MSO or family office | Written objectives on cash at close, control, pay and exit | Physician owners |
| 1 to 3 | Map federal and state review, corporate practice rules and notice requirements in every state with a site | Regulatory calendar and minimum outside date | Healthcare regulatory counsel |
| 2 to 4 | Review every ancillary line, lease and billing arrangement against federal referral and self-referral rules | Compliance memo and gap list | Regulatory counsel, compliance officer |
| 2 to 6 | Build three years of accrual financials and normalize EBITDA | Add-back schedule with physician pay shown as its own line | CFO, accounting firm |
| 4 to 8 | Commission a sell-side quality of earnings report | QoE report | Independent accounting firm |
| 4 to 6 | Model the compensation reset per physician, pre-tax and after tax, split between cash and rolled equity | Pay plan benchmarked to specialty survey data | Owners, comp consultant, tax advisor |
| 5 to 7 | Check where EBITDA falls in the size bands and test growth to the next band | Valuation range | Owners, advisor |
| 6 to 8 | Collect signed retention intent from every physician | Roster commitment letters | Managing partner |
| 6 to 9 | Build the data room | Indexed data room | Practice administrator |
| 8 to 10 | Approach PE platforms, MSOs and family offices in parallel. Verify any sell-side advisor on FINRA BrokerCheck | Comparable indications of interest | Owners, registered advisor if engaged |
| 10 to 12 | Run reverse diligence on each bidder, including Form D searches on SEC EDGAR | Reference calls, portfolio exits, fund life | Owners |
| 11 to 13 | Model cash at close, rollover outcomes, add-on funding and recurring costs for each offer | The five-line comparison table from Section 8 | Owners, advisor |
| 12 to 14 | Negotiate the 12 LOI points | Marked LOI drafts | Owners, deal counsel |
| 14 to 16 | Sign the LOI. Schedule each required filing so its review ends before the outside date | Signed LOI and filing calendar through closing | Deal counsel |
Questions physician owners ask about recaps
What is a physician practice recapitalization?
A recapitalization changes who owns the practice and how it is funded. The physicians keep practicing. In a majority recap, an investor buys control and the physicians roll part of their proceeds into the new holding company. In a minority recap, the physicians keep control and sell a smaller stake, often as new capital that goes into the practice and not to the owners. A dividend recap uses debt to fund a payout.
How much of my practice should I sell in a recap?
Work backward from three numbers: the cash you need at close, how much control you want to keep, and the exit value your rolled equity needs to reach. Majority deals pay the most cash today but require a permanent pay reset. Minority growth deals keep control and pay, but the investor's money usually goes into the practice, so the owners take little or no cash at close. Model both with post-close compensation built in before you compare offers.
What EBITDA multiple will my physician practice sell for?
Size sets the starting range. Sikich's Q3 2026 healthcare M&A update gives indicative physician practice ranges of 5 to 7x EBITDA below $1 million, 7 to 9x at $1 to 3 million, 9 to 11x at $3 to 5 million and 11 to 13x above $5 million. Specialty, payer mix and ancillary revenue move a group within its band. Sikich also reports a four- to eight-turn premium for platforms over add-on practices. Platforms are usually the larger groups, so that premium overlaps with the size bands and should not be added on top of them. Most independent groups are priced as add-ons.
How does a gross revenue royalty differ from selling equity?
A royalty pays the investor a fixed percentage of revenue every period until a return cap is reached or, in some deals, with no end date. It is paid before expenses. By our arithmetic, a 3% royalty in a practice running a 15% EBITDA margin takes 20% of EBITDA. A payment measured on professional fees raises regulatory questions, so many physician practices rule the structure out early.
Which laws can delay a physician practice recap?
Three areas most often move the closing date or the structure: state healthcare transaction notice laws, federal antitrust premerger notice for larger deals, and state corporate practice of medicine rules. Which ones apply depends on deal size, buyer type and every state where the group has sites. Map them before you agree to an outside date in the LOI.
Sources
- Bain & Company, New Models of Value Creation for Physician Groups, Global Healthcare Private Equity Report 2026
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review
- Becker's ASC Review, outpatient deal activity on PESP data, 2025
- Becker's Hospital Review, Kaufman Hall Q3 2026 hospital transaction data, 2026
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report press release, October 13, 2026
- CMS, National Health Expenditure fact sheet, 2024 data, accessed November 2026
- Sikich, Q3 2026 US Healthcare M&A Market Update and Year-End Outlook, citing PitchBook
- Buckhead FMV, Healthcare Services M&A Valuation Multiples, January 2023 to October 2026
- Axia Growth, healthcare-sector closed-sale data and physician employment data, as of October 28, 2026
- Damodaran, NYU Stern, Price and EV to Sales by Industry, US, January 2026
- Medscape Physician Compensation Report 2025, press release, April 15, 2025
- U.S. Bureau of Labor Statistics, Health Care and Social Assistance industry page, accessed November 2026
- Georgetown CHIR, State Spotlight: Oregon's multi-pronged approach to corporate influence in physician practices, accessed November 2026
- SEC EDGAR full-text search
- FINRA BrokerCheck